With its announcement of the acquisition of Accelemed Research Institute in Austin, TX, The IMA Group (IMA) continues to grow its presence in the Southwest and its capabilities in a broad range of clinical trials. The acquisition of Accelemed expands the company’s depth in multi-therapeutic clinical trial sites focused on cardiometabolic and GI diseases such as non-alcoholic steatohepatitis (NASH), obesity, high cholesterol, and diabetes. As its second Texas clinical research site and fifth in the Southwest, IMA continues to bring research opportunities to underserved and diverse communities throughout the United States. Overall, IMA Clinical Research now has 17 independent research sites nationally, including Texas, Arizona, New York, Nevada, and Florida, and 5 embedded within physician offices in Louisiana and North Carolina.
Read the full article: The IMA Group Acquires Accelemed Research Institute //
Source: https://www.businesswire.com/news/home/20230411005231/en/The-IMA-Group-Acquires-Accelemed-Research-Institute